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Abstract
Background: Recent works provide evidence of the importance of the prostaglandin D2 (PGD2) metabolic
pathway in inflammatory bowel diseases. We investigated the expression of PGD2 metabolic pathway actors
in Crohn’s disease (CD) and the ability of the enteric nervous system (ENS) to produce PGD2 in inflammatory
conditions.
Methods: Expression of key actors involved in the PGD2 metabolic pathway and its receptors was analyzed using
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in colonic mucosal biopsies of patients
from three groups: controls, quiescent and active CD patients. To determine the ability of the ENS to secrete
PGD2 in proinflammatory conditions, Lipocalin-type prostaglandin D synthase (L-PGDS) expression by neurons
and glial cells was analyzed by immunostaining. PGD2 levels were determined in a medium of primary culture
of ENS and neuro-glial coculture model treated by lipopolysaccharide (LPS).
Results: In patients with active CD, inflamed colonic mucosa showed significantly higher COX2 and L-PGDS
mRNA expression, and significantly higher PGD2 levels than healthy colonic mucosa. On the contrary, peroxysome
proliferator-activated receptor Gamma (PPARG) expression was reduced in inflamed colonic mucosa of CD patients
with active disease. Immunostaining showed that L-PGDS was expressed in the neurons of human myenteric and
submucosal plexi. A rat ENS primary culture model confirmed this expression. PGD2 levels were significantly increased
on primary culture of ENS treated with LPS. This production was abolished by AT-56, a specific competitive L-PGDS
inhibitor. The neuro-glial coculture model revealed that each component of the ENS, ECG and neurons, could
contribute to PGD2 production.
Conclusions: Our results highlight the activation of the PGD2 metabolic pathway in Crohn’s disease. This study
supports the hypothesis that in Crohn’s disease, enteric neurons and glial cells form a functional unit reacting to
inflammation by producing PGD2.
Background
Inflammatory bowel diseases (IBD) are described as multi-
factorial pathologies with an uncontrolled immune re-
sponse leading to inflammation in genetically predisposed
individuals. IBD etiologies remain unresolved [1, 2]. The
role of prostaglandins (PG) in its pathogenesis was first
suggested in 1977 [3]. Previous studies have reported high
levels of PGD2 in animal models of colitis [4, 5] and in
colonic mucosal biopsies of patients with a history of
ulcerative colitis (UC) [6]. PGD2 synthesis is derived from
prostaglandin H2 (PGH2) through prostaglandin D syn-
thase (PGDS). PGH2 is derived from arachidonic acid by
cyclooxygenases (COX), which exist in two isoforms:
COX1 and COX2. COX1 is expressed constitutively in
most cell types, whereas COX2 is induced by inflamma-
tory stimuli such as bacterial endotoxin and proinflamma-
tory cytokines. Two distinct PGDS have also been
identified: hematopoietic PGDS (HPGDS) and lipocalin-
type PGDS (L-PGDS). Similarly to COX2, L-PGDS but
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not HPGDS is known to be inducible in inflammatory con-
ditions [7, 8]. While overexpression of microsomal prosta-
glandin E synthase-1 and the proinflammatory role of
PGE2 have been well described in IBD [9], the role of
PGD2 in IBD remains debated and there have been no re-
ports on PGD2 in Crohn’s Disease (CD). Ajuebor et al.
demonstrated that PGD2 reduced granulocyte infiltration
during experimental colitis [5]. Vong et al. reported high
levels of PGD2 in the colonic tissue of patients with quies-
cent CD [6]. Some of the anti-inflammatory properties at-
tributed to PGD2 may be related to the effects of its
metabolite, 15-deoxy-Δ12,14-prostaglandin J2 (15dPGJ2),
which has been shown to exert potent anti-inflammatory
effects in animal models through activation of its receptor
PPARG [10, 11]. Conversely, Hokari et al. suggested that L-
PGDS plays a proinflammatory role in the development of
colitis in clinical and experimental studies [12]. They re-
ported that the level of L-PGDS mRNA expression was in-
creased in UC patients in parallel with disease activity.
However, changes in PGD2 production or in the expression
of enzymes involved in its synthesis during CD are cur-
rently unknown.
Although immune cells are central producers of cyto-
kines and prostaglandins; the cells of the mucosa are also
known to be able to contribute to this production [13].
The ENS is a major constituent of the intestinal mucosal
microenvironment. The ENS, composed of enteric neu-
rons and enteric glial cells (EGCs), together with the
intestinal epithelial barrier (IEB) is a functional entity, the
digestive neuronal-glial-epithelial unit, based on the phys-
ical proximity and paracrin relationship between its com-
ponents [14]. Indeed, the ENS is known to regulate the
gut homeostasis process and, in particular, intestinal epi-
thelial barrier functions, via the release of various media-
tors [14]. Recent studies have shown that the ENS is able
to sense inflammatory stressors and respond by secreting
various cytokines or chemokines [15, 16]. Furthermore,
various studies have described abnormalities of the ENS in
CD and have suggested a role of the ENS in the pathogen-
esis of IBD [17–22]. Recently, we have demonstrated that
the EGCs of the ENS are involved in controlling intestinal
epithelial functions through secretion of 15dPGJ2 [23].
However, the ability of the ENS to produce PGD2 and its
modulation by inflammation remains unknown.
Based on these findings, our aims were to investigate
expression of key actors of the PGD2 metabolic pathway
in colonic mucosal biopsies of patients with CD and to




Tissue samples were collected from colonic biopsies of
patients with CD. Thirty patients with CD treated at the
Department of Gastroenterology (Nantes University Hos-
pital, France) were included in this study. Colonic biopsies
were obtained and stored in the bio-collection of the
“Institut des Maladies de l’Appareil Digestif (IMAD)”. The
clinical and demographic data were collected and re-
corded in a computerized database securely coupled to
the biological collection. This bio-collection was approved
and registered by the French Ministry of Science and
Research “DC-2008-402”. CD was diagnosed on the basis
of clinical and endoscopic criteria. Fifteen quiescent dis-
ease patients and fifteen active disease patients, with acute
or chronic inflammation, were included in this study. Two
biopsies were collected from patients with active disease,
one in an inflamed zone and one in a normal zone.
Colonic biopsy specimens from normal mucosa were
collected from fifteen patients with colonic polyps and
were used as controls. All tissues were processed accord-
ing to the French Guidelines for Research on Human
Tissues (Agence Nationale d’Accréditation 2001). The
characteristics of patients included are given in Table 1.
After collection, biopsies were immediately immersed in
RA1 buffer (Macherey Nagel, Hoerdt, France) and stored
at – 80 °C before real-time PCR analysis. Samples
intended for PGD2 determination were stored at −80 °C
until time of use.
For immunofluorescence staining, tissue specimens
were collected from patients who underwent surgery for
colonic adenocarcinoma (four colonic specimens from
two patients were stained). Patients gave their informed
and written consent for the biopsy studies. Specimens
were taken at a distance from the tumor, in macroscopic-
ally and histologically normal areas, and immediately
processed in the Pathology Department. According to the
guidelines of the French Ethics Committee for Research
on Human Tissues, these specimens were considered as
“residual tissues”, not relevant to pathological diagnosis.
Tissue samples were subsequently fixed in 4 % parafor-
maldehyde for 3 hours at room temperature. Following
several washes in phosphate buffer saline (PBS), tissue was
pinned and whole mounts of mucosal and submucosal
plexus were obtained by microdissection under a micro-
scope SZ3060 (Olympus, Rungis, France), as previously
described [24].
Cell culture and treatments
Primary culture of the enteric nervous system
Primary culture of the rat ENS was performed as previ-
ously described [25]. Experiments were compliant with
journal policies and UK regulations on animal experi-
mentation as described by Drummond [26]. Pregnant
Sprague–Dawley rats at stage E15 were purchased
(CERJ, Le Genest St Isle, France) and manipulated in
compliance with French institutional guidelines. These
procedures were approved by the local institutional
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animal research committee (Certificate E. 44011; Inserm,
Nantes, France). Every effort was made to minimize ani-
mal suffering and the number of animals used. Rats were
killed by an overdose of CO2 followed by severing of the
carotid arteries. Intestinal cells obtained after dissection
and dissociation were counted and then seeded at a dens-
ity of 2.4 x 105 cells cm2 on 24-well plates (Corning, Avon,
France) previously coated with a 0.5 % gelatin solution
(Sigma-Aldrich, Lyon, France). Primary cultures were
maintained for 14 days with half of the medium replaced
every day (Dulbecco’s modified Eagle medium-F12 1:1
containing 1 % N-2 supplement (Life Technologies, Cergy
Pontoise, France). Primary cultures were treated for 24 h
with 0.1 μg/mL LPS (Sigma-Aldrich, Lyon, France) with
or without 95 μM AT-56 (provided by Y Urade; Osaka
Bioscience Institute) a selective and competitive inhibitor
of L-PGDS [27]. Three experiments were performed. The
ENS culture media were collected, centrifuged and stored
at −80 °C for further analysis. For immunofluorescence
staining, primary cultures of rats’ ENS were fixed in 4 %
paraformaldehyde followed by several washes in phos-
phate buffer saline (PBS).
Neuro-glial coculture model
First, a glial feeder layer was made up from the enteric
glial cell line JUG2 derived from the intestine of 15-
day-old rat embryos [28]. Briefly, the enteric glia were
plated at a density of 7,500 cells/cm2 in a 24-well plate,
and maintained for 4 days in DMEM containing 10 %
fetal calf serum, 2 mM glutamine, 50 μg/ml strepto-
mycin and 50 UI/ml penicillin. The medium was
replaced with serum-free Neurobasal/B27 medium
(Gibco) 3 h before neuron culture. Rat enteric neuron
culture was prepared from 15-day-old rat embryos by previ-
ously described methods [5], except that the dissociated cells
were plated at 175,000 cells/cm2 on glass coverslips coated
with poly-L-lysine (1 mg/ml, Sigma) in DMEM high glucose
containing 10 % FCS, 2 mM glutamine, 50 μg/ml strepto-
mycin and 50 UI/ml penicillin. The coverslips were then
transferred 3 h later to the wells containing the glial feeder
layer and maintained for up to 7 days in Neurobasal/B27 con-
taining 50 μg/ml streptomycin and 50 UI/ml penicillin. This
procedure resulted in a culture on the coverslips composed
of 82.6 ± 5.5 % of neurons and 10.6 ± 3.6 % of myofibroblasts,
while no glial cells were detected (personal observation). This
neuro-glial coculture system made it possible to physically
separate the enteric neurons and the glial cells in order to
examine the response of each cell type to LPS treatment.
RT-PCR analysis
Total RNA was extracted from human mucosal biop-
sies using the Nucleospin RNA/Protein kit (Macherey-
Nagel, Hoerdt, France). cDNA was synthesized using
standard procedures as previously described [24]. Real-
time PCR was performed according to previous reports
with some modifications [29]. Primers were designed
from the sequence of human cDNAs using the Univer-
sal Probe Library assay design center (https://lifescien-
ce.roche.com/webapp/wcs/stores/servlet/CategoryDis-
play?tab=Assay+Design+Center&identifier=Universal
+Probe+Library&langId=-1); sequences are reported in
Table 2. Amplification conditions of cPLA2-alpha,
COX1, COX2, IL1B, TNF-alpha, L-PGDS, HPGDS, D-
type prostanoid (DP) receptor 1 and 2 (DP1, DP2),
PPARG and MRPS6 templates were optimized for the
Rotorgene 3000 instrument (Qiagen, Courtaboeuf,
France). PCR amplifications were performed in dupli-
cate using Light cycler 480 SYBR Green I master mix
(Roche Diagnostics, Mannheim, Germany) according to
the manufacturer’s protocol. External standard curves
were generated with serial 5-fold dilution of cDNA
samples prepared with RNA extract from human mu-
cosal biopsies. The relative amount of transcripts was
calculated from these standard curves using RotorGene
software. Expression of S6 ribosomal proteins as in-
ternal controls was analyzed at the same time. For each
sample, the ratio between the relative amount of each spe-
cific transcript and S6 was calculated to compensate varia-
tions in the quantity and quality of starting mRNA.
Immunofluorescence staining
All antibodies were diluted in PBS with 1 mg mL−1
sodium azide, 4 % horse serum and 1 % Triton X-100. Pri-
mary cultures of rat ENS, human plexi were incubated
with PBS sodium azide horse serum and Triton X-100
followed by incubation with rabbit polyclonal anti-L-
PGDS (1:500; Cayman, Spi-Bio, Montigny-le-Bretonneux,
Table 1 Clinical characteristics and treatments - Crohn’s disease
patients at the time of study inclusion. Values are given as the
mean (minimum-maximum) for continuous variables and






Cases 15 15 15
Age, years 36 (18–63) 37 (21–76) 55 (38–76)
Sex female/male 9/8 11/4 4/11
Age at diagnosis, years 30 (19–60) 26 (15–58)
Duration of the disease,
years
7 (1–21) 12 (1–26)
Current treatment
No medication 1 (7 %) 5 (33 %)
5-ASA/Salazopyrin/
Azathioprine
2 (17 %) 2 (17 %)
Corticosteroids/
immunosuppressants
9 (60 %) 6 (40 %)
Infliximab 8 (53 %) 5 (33 %)
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France) or with human polyclonal anti-HPGDS (1:500;
Cayman Spi-Bio, Montigny-le-Bretonneux, France)
overnight at 4 °C. After extensive rinsing in PBS, pri-
mary culture or human tissues were incubated with
donkey anti-Rabbit IgG conjugated with carboxy-
methyl-indocyanin (1:500; Beckman Coulter, Roissy,
France) and donkey anti-human IgG conjugated with
carboxy-methyl-indocyanin (1:500; Molecular Probes)
for 3 h at room temperature. After L-PGDS and
HPGDS staining, primary culture or human tissues
were incubated with goat polyclonal anti-S100β (1:100;
Santa-Cruz, Tebu-Bio, Le Perrayen Yveline, France) or
with mouse anti-Hu (1:200 Molecular Probes) over-
night at 4 °C followed by donkey anti-goat IgG conju-
gated with alexa Fluor 488 (1:400; Molecular Probes),
donkey anti-mouse IgG conjugated with Alexa Fluor
488 fluorescent (1:500; Molecular Probes). Following
washes, stained samples were observed and acquired
with a IX 50 microscope (Olympus).
PGD2 assay
PGD2 levels in colonic mucosal biopsies of CD patients
or released from cell culture in incubation medium were
determined using the Prostaglandin D2-MOX EIA kit
(Cayman Chemical, MI, USA). For colonic mucosal
biopsies, acetone extraction was performed prior to
deproteinization and to concentration. Biopsies were
ground in 500 μl cold acetone on ice. Precipitated pro-
teins were removed by centrifuging at 3,000 g for 10 mi-
nutes. The sample was then evaporated to dryness under
a stream of nitrogen gas. Finally, the sample was resus-
pended in 100 μl buffer and methoximation was per-
formed according to the assay protocol.
Statistical analysis
Statistical analyses were performed using Prism 4.0
(GraphPad Software Inc., La Jolla, USA). Experimental
data were compared using a non-parametric Mann–
Whitney test, Kruskall-Wallis test followed by Dunn’s
post hoc test, Spearman test or Wilcoxon paired test. A
p value < 0.05 was considered to be significant.
Results
mRNA expression of proinflammatory cytokines is
increased in colonic biopsies from patients with active CD
To determine the inflammatory status of the colonic bi-
opsies from different groups of patients, we measured
mRNA expression of proinflammatory cytokine tumor
necrosis factor-alpha (TNF-alpha) and interleukin1,beta
(IL1B). TNF-alpha mRNA was significantly increased in
patients with active disease compared to healthy subjects
and patients with quiescent disease (Fig 1a). Five pa-
tients with quiescent disease also presented with an in-
crease in TNF-alpha expression. This transcriptional
status was equivalent to that of patients with active CD.
This increase was not associated with any relevant clin-
ical characteristics or treatment. IL1B mRNA was sig-
nificantly increased in sites of intestinal inflammation in
patients with active CD compared to the other three
groups: controls, biopsies from patients with quiescent
disease and from normal mucosa of patients with active
CD (Fig 1b).
L-PGDS mRNA expression and PGD2 levels were
increased in inflamed colonic mucosa of patients with
active CD
We then examined mRNA expression of the five key en-
zymes involved in PGD2 production and its receptors.
Cytoplasmic Phospholipase A2 (cPLA2-alpha) and COX1
were up-regulated in the mucosa of patients with active
CD and in the mucosa of five patients with quiescent dis-
ease (Fig 2a-b). In patients with active CD, COX2 mRNA
expression was significantly increased in the inflamed zone
compared to the normal zone (Fig 2c). Colonic expression
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of HPGDS in colonic biopsy specimens from patients
with quiescent CD did not differ significantly from that
of controls (Fig 2d). HPGDS mRNA levels were re-
duced in the inflamed zone of patients with active CD.
L-PGDS mRNA expression was significantly higher in
the inflamed colonic mucosa of patients with active CD
than in normal mucosa of CD patients or controls
(Fig 2e). TNF-alpha mRNA expression was significantly
correlated with cPLA2-alpha (r = 0.8245; p < 0.0001) and
COX1 (r = 0.84; p < 0.0001) expression while IL1B mRNA
expression was significantly correlated with COX2 (r =
0.82, p < 0.0001) and L-PGDS (r = 0.48; p < 0.0001)
expression. Only the inflamed zone in active CD
showed total activation of the PGD2 metabolic pathway
with up-regulation of cPLA2-alpha, COX1, COX2 and
L-PGDS.
We quantified DP1, DP2 and PPARG mRNA expres-
sion in the same samples (Fig 3). The colonic expres-
sion of DP1 and DP2 in colonic biopsy specimens from
patients with CD did not differ significantly from that
of controls except for the expression of DP2 which was
reduced in inflamed colonic mucosa of CD patients
with active disease compared with mucosa of CD pa-
tients with quiescent disease (Fig 3a-b). PPARG ex-
pression was reduced in inflamed colonic mucosa of
CD patients with active disease compared with non-
inflamed mucosa of CD patients with active disease,
mucosa of CD patients with quiescent disease or con-
trol mucosa (Fig 3c).
To determine whether activation could lead to higher
PGD2 production, we measured PGD2 levels in the co-
lonic biopsies of CD patients. In patients with active CD,
PGD2 levels were significantly higher in inflamed colonic
mucosa than in normal colonic mucosa (Fig 4).
Neurons of the enteric nervous system express Lipocalin
prostaglandin D synthase
L-PGDS expression by EGCs has been previously de-
scribed [23]. To determine whether enteric neurons could
also express L-PGDS, the main enzyme responsible for
PGD2 synthesis in inflammatory conditions, we per-
formed L-PGDS immunofluorescence labeling in human
myenteric (Fig 5a) and in human submucosal plexi
(Fig 5b). Neurons were selectively stained using antibodies
directed against the neuronal protein Hu C/D. We found
that L-PGDS was expressed in neurons of both human
myenteric and submucosal plexi. HPGDS was not
expressed by ENS components (data not provided).
ENS produced PGD2 via L-PGDS in proinflammatory
conditions
First, L-PGDS expression by glial and neuronal cells in
rat ENS primary culture was verified by immunostaining
(Fig 6a-b). In contrast, HPGDS was not detected in rat
ENS primary culture (data not provided). In order to
evaluate the capacity of the ENS to produce PGD2 in
proinflammatory conditions, primary cultures were
treated for 24 h with LPS without or with AT-56, a spe-
cific competitive L-PGDS inhibitor. LPS was used to in-
duce an inflammatory stress. We showed that 1/ the
ENS produced PGD2 in response to LPS, and 2/ at the
IC50 concentration (95 μM) AT-56 reduced PGD2 pro-
duction in response to LPS (Fig 7a). These results con-
firmed that the ENS is able to produce PGD2 in
proinflammatory conditions through L-PGDS. To deter-
mine the contribution of neurons and glial cells to the
production of PGD2, a neuro-glial coculture model, in
which neurons were plated on a glass coverslip sus-
pended above a glia layer, was treated with LPS for 24 h.
Fig. 1 Quantitative RT-PCR analysis of TNF-alpha (a) and IL1B (b) gene expression in colonic biopsies from healthy subjects (CTRL), CD patients
with quiescent disease or active disease (normal zone and inflamed zone). Data were normalized to MRPS6 gene expression (n = 15; ***p <0.001;
**p < 0.01; *p < 0.5, Kruskall-Wallis test followed by Dunn’s post hoc test)
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LPS treatment of the coculture model induced increased
PGD2 production, as observed with ENS primary culture
(Fig 7b). After 6 days’ co-culture, glial cells and neurons
were then separated and treated with LPS for 24 h
(Fig 7c-d). We observed increased PGD2 production in
isolated neurons and glial cells, suggesting that both en-
teric neurons and EGCs were able to produce PGD2 in
proinflammatory conditions.
Discussion
Our work showed for the first time that there is activa-
tion of the entire PGD2 metabolic pathway by increase
in mRNA expression of cPLA2-alpha, COX1, COX2
and L-PGDS in the inflamed zone of the colonic mu-
cosa in active CD. Activation leads to increased PGD2
levels in inflamed colonic mucosa. Furthermore, our re-
sults showed that the ENS, both cellular components,
Fig. 2 Quantitative RT-PCR analysis of cPLA2 (a), COX1 (b), HPGDS (c), COX2 (d), L-PGDS (e), gene expression in colonic biopsies from healthy
subjects (CTRL), CD patients with quiescent disease or active disease (normal zone and inflamed zone). Data were normalized to MRPS6 gene
expression (n = 15; ***p <0.001; **p < 0.01; *p < 0.5, Kruskall-Wallis test followed by Dunn’s post hoc test)
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ECG and neurons, can contribute to PGD2 production
in response to proinflammatory stress.
In colonic biopsies of CD patients, we reported two
activation profiles respectively associated with TNF-
alpha and IL1B proinflammatory cytokines expression: a
total activation profile involving TNF-alpha, IL1B,
cPLA2-alpha, COX1, COX2 and L-PGDS, and inter-
mediate activation profile, involving TNF-alpha, cPLA2-
alpha and COX1 observed both in the normal zone of
colonic mucosa in active and quiescent CD. This inter-
mediate profile is found in the normal zone of colonic
mucosa in the 15 patients with active CD but only in 5
patients with quiescent CD. Among quiescent patients,
these five patients did not show any obvious clinical
differences from other quiescent patients. These five pa-
tients presented a transcriptional status equivalent to
that of active CD patients. No histological analysis was
done on these colonic biopsy specimens. Such analysis
could clarify this result which could be secondary to the
accumulation of inflammatory cells in the tissue. On the
other hand, to identify other actors implicated in the sig-
naling pathways involved in these two distinct inflamma-
tory profiles, it would be interesting to compare the
transcriptome of patients with active and quiescent CD
by performing microarray studies.
Interestingly, COX1 mRNA expression was upregu-
lated in all patients with active CD and in five patients
with quiescent CD. COX1 is usually known to be a con-
stitutive enzyme playing physiological roles, not involved
in inflammatory responses [30]. However, high expres-
sion of COX1 has already been reported in gastric mu-
cosa in inflammatory situations, where COX1-activity
was involved in thromboxane A2 (TXA2) synthesis [31].
Hawkey et al. have reported increased TXA2 synthesis
in non-inflamed rectal mucosa of CD patients [32], sug-
gesting that COX1-TXA2 activation, leading to platelet
aggregability and local vasoconstriction, is also of import-
ance in CD. Therefore, COX1 and COX2 are probably
both involved in mucosal integrity through different lipid
mediators.
In accordance with a previous study [33, 34], we
showed up-regulation of IL1B and COX2 expression in
the inflamed zone of the colon in patients with active
CD. A significant increase in mucosal expression of
COX2, the main enzyme responsible for PG production
in inflamed mucosa had been already reported [33, 34].
Here, we showed, for the first time, an up-regulation of
L-PGDS expression and an increased synthesis of PGD2
in CD. Our data are in keeping with recent results from
Hokari et al. in UC [12]. They demonstrated that L-
PGDS was up-regulated in severely inflamed mucosa
and correlated with disease activity, suggesting inflam-
matory action. The mechanism by which the L-PGDS
gene is up-regulated in inflammatory situations is par-
tially described. Fujimory et al. demonstrated that L-
Fig. 3 Quantitative RT-PCR analysis of DP1 (a), DP2 (b), PPARG (c) gene expression in colonic biopsies from healthy subjects (CTRL), CD patients
with quiescent disease or active disease (normal zone and inflamed zone). Data were normalized to MRPS6 gene expression (n = 15; ***p <0.001;
**p < 0.01; *p < 0.5, Kruskall-Wallis test followed by Dunn’s post hoc test)
Fig. 4 PGD2 assays in paired colonic mucosal biopsies from patients
with active CD. Normal zone (n = 7) versus inflamed zone (n = 7).
(*P < 0.5, Wilcoxon paired test)
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PGDS gene expression is up-regulated by IL-1β [35]. In
rats, two NF-Kappa B elements, present on the L-PGDS
gene promoter region, are essential to up-regulation.
Conversely, HPGDS expression was not increased in the
inflamed mucosa of patients with active disease. In the
gut, although HPGS is the most important form of
PGDS, expressed by intestinal epithelial cells, mast cells
and fibroblasts [7, 36], our data suggests that PGD2 de-
rived from L-PGDS plays a greater role in the patho-
physiology of CD.
In our study, we showed that PPARG is down regu-
lated in inflamed colonic mucosa of CD patients with
active disease. The colonic expression of the two distinct
PGD2 receptors DP1 and DP2 in colonic biopsy speci-
mens from patients with CD did not differ significantly
from that in controls except for the expression of DP2
specifically reduced in inflamed colonic mucosa of CD
patients with active disease compared with mucosa of
CD patients with quiescent disease. The biological effect
of PGD2 on intestinal inflammation remains widely
debated. Only, few studies analyzed the role of PGD2 in
an intestinal inflammatory process, with opposite roles
[5, 6, 37, 38]. Functional duality of PGD2 is probably
based on the differential expression in human IBD of the
three potential receptors activated by PGD2 or its me-
tabolite, 15dPGJ2. 15dPGJ2 plays an anti-inflammatory
or immunomodulatory role through PPARG, which is
expressed at high levels in the colonic epithelium. The
downregulation of PPARG suggests the inability of
15dPGJ2, PGD2 metabolite, to execute completely its anti-
inflammatory effects. The two distinct PGD2 receptors
DP1 and DP2 are G protein coupled but signal via differ-
ent second messengers. Engagement of DP1 results in
protein kinase A activation [39] while DP2 acts to raise
intracellular calcium levels [40]. PGD2 and 15dPGJ2 are
both ligands for DP1 and DP2 [41]. Activation of DP1
Fig. 5 Immunofluorescence staining of L-PGDS in human plexi. In human myenteric (a) and submucosal plexi (b), Hu was colocalized with L-PGDS.
Scales bars are 40 μm (a-b). Typical picture of four colonic tissues obtained in healthy area of two patients who underwent surgery for
colonic adenocarcinoma
Fig. 6 Immunofluorescence staining of L-PGDS in primary culture of rat ENS. In primary culture of rat ENS, Hu (a) and S100β (b) were colocalized
with L-PGDS. Scales bars are 50 μm (A-B)
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leads to beneficial effects. Reduction of granulocyte infiltra-
tion through DP1 activation was observed in a colitis
model [5]. In colon biopsies of patients with UC,
Vong et al. reported that PGD2 contributes to main-
taining remission in patients. They observed increased
PGD2 synthesis and increased DP1 receptor expression
[6]. Some studies also showed that DP1 receptor activa-
tion stimulates mucin secretion, MUC2 and MUC5AC
[42, 43]. The main function of mucins is to protect the co-
lonic mucosa [44]. MUC2 and MUC5AC are involved in
epithelial repair in IBD by acting on cell differentiation
and growth [45]. The beneficial role of PGD2 in CD may
also be attributed to DP1 activation. PGD2 also plays
an important role through DP2 activation by down-
regulating neutrophil infiltration into the mucosa in
acute colitis. In a sepsis mouse model, PGD2 and
15dPGJ2 were significantly increased in peritoneal fluid.
Furthermore, COX2 and L-PGDS were up-regulated in
the peritoneal exudate cells. In this model, DP2−/−
mice exhibited a significantly higher accumulation of
neutrophils into the peritoneal cavity compared with
wild type mice [40].
Our study provides evidence on the origin of PGD2 in
colitis. Enteric neurons and enteric glial cells are potent
modulators of the intestinal epithelial barrier (IEB) and
are involved in pathologies associated with altered bar-
rier functions. EGC and neurons produce soluble factors
known to regulate intestinal epithelial barrier functions
[14, 21, 24, 46]. PGD2 also seems to play a role in this
relationship. Previously, we reported that EGCs express
L-PGDS and are a cellular source of 15dPGJ2, which
regulate epithelial cell proliferation and differentiation
via PPARG activation [23]. Here, we first demonstrated
that enteric neurons express L-PGDS but not HPGDS.
Secondly, we showed that neurons and glial cells secrete
PGD2 through L-PGDS in proinflammatory conditions.
Thus, the ENS is a source of PGD2 in response to in-
flammatory stress which regulates IEB functions.
These data are consistent with the ENS’s involvement in
IBD pathogenesis. Altogether, enteric neurons, enteric
glial cells and the IEB constitute a functional entity, the di-
gestive neuronal-glial-epithelial unit, based on physical
proximity and paracrin relations between its components
[14]. The ENS is known to regulate the gut homeostasis
Fig. 7 Enteric nervous system and PGD2 production in inflammatory conditions. Primary culture of ENS with and without LPS +/− AT-56
(95 μM) (a) (n = 12); coculture of ECG with neurons +/− LPS (b), EGCs culture +/− LPS (c), Neurons culture +/− LPS (d). Data were
expressed as mean +/− SEM (n = 8), (Kruskall-Wallis test followed by Dunn’s post hoc test was used for Fig. 6a, Mann–Whitney test was
used for Fig 6b, c, d)
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process, and, in particular, intestinal epithelial barrier
functions, via the release of various mediators [14]. In
colitis, epithelial function is impaired, leading to ele-
vated bacterial translocation. In the submucosal plexus,
neurons and glial cells expressing Toll-like receptor 4,
may participate in an adaptative reaction and may be
engaged in the defense responses of the intestinal bar-
rier [47]. This cellular reaction is similar to the proin-
flammatory process named reactive astrogliosis in the
central nervous system (CNS). Immediately after CNS
injury, glial cells undergo rapid morphological changes.
Interestingly, L-PGDS, which is expressed by glial cells
in the central nervous system, participates in reactive
gliosis in an autocrine or paracrine manner, and may
have pathological implications in neuroinflammatory
diseases.
Conclusion
Emerging data suggest that paracrine communication
between enteric neurons, glial cells and IEC regulate key
functions and is involved in controlling IEB homeostasis.
The PGD2 metabolic pathway implicating L-PGDS ap-
pears to be activated in Crohn’s disease. This study dem-
onstrates that L-PGDS, expressed in intestinal neurons
and glial cells, is up-regulated in the inflamed colonic
mucosa of patients with active CD. More detailed studies
are necessary to elucidate the mechanism relating to in-
volvement of the PGD2 pathway in CD. The next step
will be identification of PGD2 targets in the IEB. It may
reveal new targeted therapeutic options in CD.
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